JP2007536359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007536359A5 JP2007536359A5 JP2007512321A JP2007512321A JP2007536359A5 JP 2007536359 A5 JP2007536359 A5 JP 2007536359A5 JP 2007512321 A JP2007512321 A JP 2007512321A JP 2007512321 A JP2007512321 A JP 2007512321A JP 2007536359 A5 JP2007536359 A5 JP 2007536359A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- ltb
- biosynthesis
- function
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003112 inhibitor Substances 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 9
- 230000015572 biosynthetic process Effects 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 239000002246 antineoplastic agent Substances 0.000 claims 5
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 4
- 208000003950 B-cell lymphoma Diseases 0.000 claims 4
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 4
- 230000007246 mechanism Effects 0.000 claims 2
- 101100236208 Homo sapiens LTB4R gene Proteins 0.000 claims 1
- 102100033374 Leukotriene B4 receptor 1 Human genes 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- CEUDWZXMLMKPNN-SOFGYWHQSA-N n-hydroxy-n-[(e)-3-(3-phenoxyphenyl)prop-2-enyl]acetamide Chemical compound CC(=O)N(O)C\C=C\C1=CC=CC(OC=2C=CC=CC=2)=C1 CEUDWZXMLMKPNN-SOFGYWHQSA-N 0.000 claims 1
Claims (10)
- ＬＴＢ ４ の生合成及び／又は機能のインヒビターを含むＢ-ＣＬＬ、Ｂ-ＰＬＬ又はＢ細胞リンパ腫の治療薬。
- ＬＴＢ４の生合成及び／又は機能のインヒビターが、患者に投与される唯一の癌化学療法剤である、請求項１に記載の治療薬。
- ＬＴＢ４の機能のインヒビターが、ＢＬＴ１レセプターのアンタゴニストである、請求項１又は２に記載の治療薬。
- ＬＴＢ４の生合成のインヒビターが、５-ＬＯのインヒビター、ＦＬＡＰのインヒビター、及び／又はＬＴＡ４加水分解酵素のインヒビターである、請求項１又は２に記載の治療薬。
- ５-ＬＯのインヒビターがＢＷＡ４Ｃであり、又はＦＬＡＰのインヒビターがＭＫ-８８６である、請求項４に記載の治療薬。
- 異なる作用機序を有する癌化学療法剤と併用される、ＬＴＢ ４ の生合成及び／又は機能のインヒビターを含有するＢ-ＣＬＬ、Ｂ-ＰＬＬ又はＢ細胞リンパ腫の治療薬。
- (Ａ)ＬＴＢ４の生合成及び／又は機能のインヒビター、又はその薬学的に許容可能な誘導体と；
(Ｂ)異なる作用機序を有する癌化学療法剤、又はその薬学的に許容可能な誘導体；
を含有し、各成分(Ａ)及び(Ｂ)が薬学的に許容可能なアジュバント、希釈液又は担体と混合されて製剤化される組合せ品。 - Ｂ-ＣＬＬ、Ｂ-ＰＬＬ又はＢ細胞リンパ腫を治療するための医薬の調製における、ＬＴＢ４の生合成及び／又は機能のインヒビターの使用。
- ＬＴＢ４の生合成及び／又は機能のインヒビターが、医薬の調製に使用される唯一の癌化学療法剤である、請求項８に記載の使用。
- 異なる作用機序を有する癌化学療法剤が投与される患者のＢ-ＣＬＬ、Ｂ-ＰＬＬ又はＢ細胞リンパ腫を治療するための医薬の調製における、ＬＴＢ４の生合成及び／又は機能のインヒビターの使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56826204P | 2004-05-06 | 2004-05-06 | |
| GBGB0410103.6A GB0410103D0 (en) | 2004-05-06 | 2004-05-06 | New method |
| PCT/GB2005/001724 WO2005107725A1 (en) | 2004-05-06 | 2005-05-05 | Use of ltb4 inhibitors for the treatment of b-cell leukemias and lymphomas |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007536359A JP2007536359A (ja) | 2007-12-13 |
| JP2007536359A5 true JP2007536359A5 (ja) | 2008-06-26 |
Family
ID=32482771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007512321A Withdrawn JP2007536359A (ja) | 2004-05-06 | 2005-05-05 | Ｂ細胞の白血病及びリンパ腫の治療のためのｌｔｂ４インヒビターの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080081835A1 (ja) |
| EP (1) | EP1742622A1 (ja) |
| JP (1) | JP2007536359A (ja) |
| GB (1) | GB0410103D0 (ja) |
| WO (1) | WO2005107725A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9732320B2 (en) | 2008-01-18 | 2017-08-15 | The Brigham And Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human TH17 cells |
| EP2238241B1 (en) * | 2008-01-18 | 2013-09-11 | The Brigham and Women's Hospital, Inc. | Selective differentiation, identification, and modulation of human th17 cells |
| CA2709808A1 (en) * | 2008-05-21 | 2009-11-26 | Teikoku Pharma Usa, Inc. | Treatment of dysmenorrhea via transdermal administration of nonsteroidal anti-inflammatory drugs |
| GB0810011D0 (en) * | 2008-06-02 | 2008-07-09 | Jackson William P | 5-Lipoxygenase inhibitors |
| UA117498C2 (uk) | 2013-12-20 | 2018-08-10 | Новартіс Аг | Гетероарильні похідні бутанової кислоти як інгібітори lta4h |
| CN115068486A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 乳香酸类化合物作为ltb4受体抑制剂的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU698313B2 (en) * | 1994-03-14 | 1998-10-29 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents |
| GB2290707A (en) * | 1994-06-28 | 1996-01-10 | Georgi Stankov | Pharmaceutical uses of Amphotericin B |
| JP2003511045A (ja) * | 1999-10-04 | 2003-03-25 | ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュー ジャージー | Ｒｎａ結合化合物の同定方法 |
| AU1595101A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| WO2001034133A2 (en) * | 1999-11-11 | 2001-05-17 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1592901A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| AU1917101A (en) * | 1999-11-11 | 2001-06-06 | Eli Lilly And Company | Oncolytic combinations for the treatment of cancer |
| CA2697599A1 (en) * | 2002-02-08 | 2003-08-14 | John David Allard | Method of treating and preventing bone loss |
| JP2003252763A (ja) * | 2002-02-27 | 2003-09-10 | Yuichiro Kamikawa | 抗腫瘍剤 |
| US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| EP1623231A2 (en) * | 2003-05-06 | 2006-02-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) |
-
2004
- 2004-05-06 GB GBGB0410103.6A patent/GB0410103D0/en not_active Ceased
-
2005
- 2005-05-05 US US11/579,474 patent/US20080081835A1/en not_active Abandoned
- 2005-05-05 WO PCT/GB2005/001724 patent/WO2005107725A1/en active Application Filing
- 2005-05-05 JP JP2007512321A patent/JP2007536359A/ja not_active Withdrawn
- 2005-05-05 EP EP05741939A patent/EP1742622A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008501705A5 (ja) | ||
| EP2444072A3 (en) | Non-mucoadhesive film dosage forms | |
| RU2007132181A (ru) | ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ | |
| JP2007536359A5 (ja) | ||
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| WO2007075554A3 (en) | Combination of igfr inhibitor and anti-cancer agent | |
| WO2005046318A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders | |
| MY130803A (en) | New quinuclidine amide derivatives | |
| JP2009513713A5 (ja) | ||
| WO2005044178A3 (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
| ECSP066878A (es) | [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa | |
| IL184116A0 (en) | Use of thiazolidinone derivatives as antiangiogenic agents | |
| WO2007054514A3 (en) | Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure | |
| CA2530308A1 (en) | 5ht2c receptor agonists for the treatment of diabetes and obesity | |
| EP2275110A3 (en) | Cladribine regimen for treating Multiple Sclerosis | |
| JP2007525533A5 (ja) | ||
| AR060284A1 (es) | Terapia de combinacion de (2r,z)-2-amino-2-ciclohexil-n-(5-(1-metil-1h- pirazol- 4-il)-1- oxo- 2,6 dihidro-1h- [1,2] diazepino [4,5,6-cd] indol-8-il) acetamida | |
| JP2006511538A5 (ja) | ||
| JP2008535812A5 (ja) | ||
| WO2010092436A1 (en) | Pharmaceutical combinations of simethicone and otilonium | |
| JP2008519073A (ja) | チプラナビル及びエトラビリンの同時投与によるｈｉｖ感染症の治療法 | |
| MXPA05009849A (es) | Terapia combinada que comprende nemorubicina y un inhibidor de la ciclooxigenasa-2. | |
| TW200602329A (en) | Novel diazine derivatives, their manufacture and use as pharmaceutical agents | |
| JP2005533075A5 (ja) | ||
| JP2008520701A (ja) | チプラナビル及びレバーセットの同時投与を介したｈｉｖ感染症の治療方法 |